Financials Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 10:48:47 2025-12-08 EST			5-day change	1st Jan Change
121.81 ^USD	+0.49%		-1.88%	+32.07%

07:49am	Gilead Sciences' Kite Says Yescarta Shows 'Consistent' Benefits in Large B-cell Lymphoma	MT
07:18am	Gilead Unit Reports Encouraging Phase 1 Data Showing High Response Rates for Bicistronic CAR T-Cell Candidates in B-Cell Lymphoma	MT

Projected Income Statement: Gilead Sciences, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net sales ¹	24,689	27,305	27,281	27,116	28,754	29,208	30,082	31,540
Change	-	10.6%	-0.09%	-0.6%	6.04%	1.58%	2.99%	4.85%
EBITDA ¹	13,184	14,598	14,283	13,177	11,287	15,976	16,551	17,258
Change	-	10.73%	-2.16%	-7.74%	-14.34%	41.55%	3.6%	4.27%
EBIT ¹	11,704	12,548	12,180	10,484	8,520	13,286	14,075	14,991
Change	-	7.21%	-2.93%	-13.92%	-18.73%	55.94%	5.94%	6.51%
Interest Paid ¹	-984	-1,001	-935	-944	-977	-982.5	-923.2	-902.3
Earnings before Tax (EBT) ¹	1,669	8,278	5,814	6,859	690	10,022	10,871	11,502
Change	-	395.99%	-29.77%	17.97%	-89.94%	1,352.39%	8.48%	5.8%
Net income ¹	123	6,225	4,592	5,665	480	8,282	8,943	9,633
Change	-	4,960.98%	-26.23%	23.37%	-91.53%	1,625.4%	7.99%	7.71%
Announcement Date	2/4/21	2/1/22	2/2/23	2/6/24	2/11/25	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4
Net sales ¹	7,421	6,423	6,217	7,421	7,244	6,590	6,260	7,042	7,389	6,352	6,599	7,051	7,115	6,686	6,954	7,545	7,569	6,667	7,082	7,769	7,653	7,036	7,490	7,743	8,144
Change	-	-13.45%	-3.21%	19.37%	-2.39%	-9.03%	-5.01%	12.49%	4.93%	-14.03%	3.89%	6.85%	0.91%	-6.03%	4.01%	8.5%	0.32%	-11.92%	6.22%	9.7%	-1.5%	-8.06%	6.46%	3.38%	5.17%
EBITDA ¹	3,919	3,959	3,695	4,902	2,042	4,049	3,195	3,811	3,227	2,883	3,258	3,908	3,427	-427	3,959	3,948	3,807	3,589	3,981	4,607	4,386	3,924	4,200	4,375	4,500
Change	-	1.02%	-6.67%	32.67%	-58.34%	98.29%	-21.09%	19.28%	-15.32%	-10.66%	13.01%	19.95%	-12.31%	-112.46%	1,027.17%	-0.28%	-3.57%	-5.73%	10.92%	15.72%	-4.8%	-10.53%	7.02%	4.18%	2.86%
EBIT ¹	3,492	3,486	3,176	4,379	1,507	3,524	2,670	3,286	2,699	2,243	2,277	3,224	2,739	-1,117	3,265	3,258	3,114	2,893	3,290	3,921	3,145	3,192	3,489	3,723	3,825
Change	-	-0.17%	-8.89%	37.88%	-65.59%	133.84%	-24.23%	23.07%	-17.86%	-16.9%	1.52%	41.59%	-15.04%	-140.78%	392.3%	-0.21%	-4.42%	-7.1%	13.72%	19.18%	-19.79%	1.5%	9.29%	6.71%	2.75%
Charge d'intérêts ¹	-267	-257	-256	-250	-238	-238	-242	-229	-227	-230	-230	-232	-252	-254	-237	-238	-248	-260	-254	-256	-237.4	-238.8	-235.8	-235.1	-224.8
Earnings before Tax (EBT) ¹	1,814	2,264	1,817	3,438	759	-152	1,503	2,432	2,031	1,300	1,588	2,318	1,653	-4,486	2,053	956	2,168	1,649	2,429	3,641	2,303	2,603	3,187	2,827	2,950
Change	-	24.81%	-19.74%	89.21%	-77.92%	-120.03%	1,088.82%	61.81%	-16.49%	-35.99%	22.15%	45.97%	-28.69%	-371.39%	145.76%	-53.43%	126.78%	-23.94%	47.3%	49.9%	-36.76%	13.04%	22.44%	-11.3%	4.35%
Net income ¹	1,551	1,729	1,522	2,592	382	19	1,144	1,789	1,640	1,010	1,045	2,180	1,429	-4,170	1,614	1,253	1,783	1,315	1,960	3,052	1,980	2,071	2,430	2,393	2,410
Change	-	11.48%	-11.97%	70.3%	-85.26%	-95.03%	5,921.05%	56.38%	-8.33%	-38.41%	3.47%	108.61%	-34.45%	-391.81%	138.71%	-22.37%	42.3%	-26.25%	49.05%	55.71%	-35.14%	4.62%	17.33%	-1.52%	0.69%
Announcement Date	2/4/21	4/29/21	7/29/21	10/28/21	2/1/22	4/28/22	8/2/22	10/27/22	2/2/23	4/27/23	8/3/23	11/7/23	2/6/24	4/25/24	8/8/24	11/6/24	2/11/25	4/24/25	8/7/25	10/30/25	-	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: Gilead Sciences, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net Debt ¹	30,879	27,449	18,845	17,723	16,720	12,716	6,113	354
Change	-	-11.11%	-31.35%	-5.95%	-5.66%	-23.95%	-51.93%	-94.21%
Announcement Date	2/4/21	2/1/22	2/2/23	2/6/24	2/11/25	-	-	-

¹USD in Million

Estimates

Cash Flow Forecast: Gilead Sciences, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
CAPEX ¹	650	579	728	585	523	568.6	594.9	622.3
Change	-	-10.92%	25.73%	-19.64%	-10.6%	8.71%	4.62%	4.62%
Free Cash Flow (FCF) ¹	7,518	10,805	8,344	7,421	10,305	10,767	12,658	13,193
Change	-	43.72%	-22.78%	-11.06%	38.86%	4.49%	17.56%	4.23%
Announcement Date	2/4/21	2/1/22	2/2/23	2/6/24	2/11/25	-	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: Gilead Sciences, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Profitability
EBITDA Margin (%)	53.4%	53.46%	52.36%	48.59%	39.25%	54.7%	55.02%	54.72%
EBIT Margin (%)	47.41%	45.95%	44.65%	38.66%	29.63%	45.49%	46.79%	47.53%
EBT Margin (%)	6.76%	30.32%	21.31%	25.3%	2.4%	34.31%	36.14%	36.47%
Net margin (%)	0.5%	22.8%	16.83%	20.89%	1.67%	28.35%	29.73%	30.54%
FCF margin (%)	30.45%	39.57%	30.59%	27.37%	35.84%	36.86%	42.08%	41.83%
FCF / Net Income (%)	6,112.2%	173.57%	181.71%	131%	2,146.88%	130.01%	141.54%	136.96%
Profitability
ROA	0.19%	9.13%	13.97%	13.49%	9.57%	14.65%	15.23%	14.71%
ROE	43.84%	46.79%	43.33%	38.46%	27.6%	44.96%	38.3%	34.86%
Financial Health
Leverage (Debt/EBITDA)	2.34x	1.88x	1.32x	1.34x	1.48x	0.8x	0.37x	0.02x
Debt / Free cash flow	4.11x	2.54x	2.26x	2.39x	1.62x	1.18x	0.48x	0.03x
Capital Intensity
CAPEX / Current Assets (%)	2.63%	2.12%	2.67%	2.16%	1.82%	1.95%	1.98%	1.97%
CAPEX / EBITDA (%)	4.93%	3.97%	5.1%	4.44%	4.63%	3.56%	3.59%	3.61%
CAPEX / FCF (%)	8.65%	5.36%	8.72%	7.88%	5.08%	5.28%	4.7%	4.72%
Items per share
Cash flow per share ¹	6.467	9.021	7.189	6.364	8.628	10.1	11.3	12.43
Change	-	39.48%	-20.31%	-11.47%	35.57%	17.09%	11.85%	10%
Dividend per Share ¹	2.72	2.84	2.92	3	3.08	3.308	3.458	3.605
Change	-	4.41%	2.82%	2.74%	2.67%	7.39%	4.54%	4.25%
Book Value Per Share ¹	14.43	16.8	17.01	18.08	15.45	18.28	21.94	25.84
Change	-	16.41%	1.25%	6.32%	-14.58%	18.37%	19.98%	17.79%
EPS ¹	0.1	4.93	3.64	4.5	0.38	6.855	7.494	8.078
Change	-	4,830%	-26.17%	23.63%	-91.56%	1,703.83%	9.32%	7.8%
Nbr of stocks (in thousands)	1,253,528	1,254,384	1,254,244	1,246,042	1,246,266	1,240,680	1,240,680	1,240,680
Announcement Date	2/4/21	2/1/22	2/2/23	2/6/24	2/11/25	-	-	-